Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi
Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 2025.
Dry eye disease (DED) affects a substantial proportion of the population in China, with reported prevalence ranging from approximately 21.0% to 52.4% 1. DED is a multifactorial disorder driven by disruption of tear film homeostasis and a self-perpetuating vicious cycle of inflammation 1,2,3. This vicious circle results in subjective symptoms - such as dryness, foreign body sensation and burning - and clinical signs of ocular surface damage, impairing visual function and quality of life 3. Current treatment strategies remain limited, often falling short of meeting the combined requirements for efficacy, safety, and suitability for long-term use, highlighting a significant unmet medical need in DED management.
